Qiagen (QGEN) said Monday it filed a patent infringement complaint in Germany against bioMerieux to protect its QuantiFERON technology for tuberculosis diagnostics.
The complaint is related to European Patent EP 2 276 883 B2, the company said.
bioMerieux did not immediately reply to MT Newswires' request for comment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.